Actionable news
0
All posts from Actionable news
Actionable news in AEZS: AEterna Zentaris Inc.,

​Sarepta SRPT shares +14% on earnings; Aeterna Zentaris AEZS +129% on acceptance of NDA + offerings galore

Price and Volume Movers

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are trading up 14% in the after-hours session to $38.70 following better than expected sales data reported in its 2Q earnings release. Sales from Exondys 51, approved by the FDA in 2016 for the treatment of Duchenne muscular dystrophy, were $35m in 2Q 2017, above market estimates of around $22m. Guidance was also raised for 2017 to between $125m and $130m, above previous consensus of $105m.

Shares of Aeterna Zentaris Inc. (NASDAQ: AEZS) surged to close up 129% to $2.34. The company announced Tuesday that its New Drug Application (NDA) seeking approval of Macrilen (macimorelin) for the evaluation of growth hormone deficiency in adults (AGHD) has been granted a PDUFA date of December 30, 2017. The resubmission follows the Complete Response Letter (CRL) issued in November 2014 and its failed Phase 3 trial in January 2017. At the time of its release of data from the Phase 3 trial, the company’s Chief Scientific Officer noted;

We are, of course, very disappointed about the...


More